Aldevron News: Antibody

Aldevron The First To Rapidly Discover Human Antibodies Using Ligands Omnirat® Platform And Berkeley Lights Beacon® Instrument

Aldevron, a leading provider of antibody discovery and production services, today announced the successful discovery of human antibodies utilizing the combination of three powerful platforms, Aldevron’s GENOVAC® genetic immunization and cell-based screening, Ligand’s OmniRat® therapeutic antibody platform and Berkeley Lights’ Beacon® platform.

Read More

Aldevron's Antibody Discovery Team Participating at PEGS

Patricia Odermatt, Senior B-cell Scientist with Aldevron’s Antibody business unit, will be presenting at the  PEGS Boston Summit at 11:30 EDT on Monday, August 31. Her presentation,  Rapid Human Antibody Discovery Utilizing Ligand’s OmniRat® Platform and Berkeley Lights’ Beacon® Instrument will show how three antibody discovery platforms are being used together in developing fully human antibodies against SARS-CoV-2 targets. Patricia will be available at the Aldevron digital booth for additional discussions throughout PEGS. The presentation is only available to those registered for PEGS, which you can find here. However, anyone can connect with our Antibody team at any time through our contact form.
Read More

Aldevron now utilizing Berkeley Lights' Beacon® platform

Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic platform (Beacon) to support rapid execution of species agnostic single B-cell antibody discovery to complement its industry-leading genetic immunization and hybridoma capabilities.

The Beacon platform will be located in the recently announced expansion lab space in Aldevron’s Freiburg, Germany, facility and will be coming on-line in June 2019. Aldevron is the first CRO in Germany to adapt this new technology for antibody discovery.

Read More

Aldevron Announces Antibody Facility Expansion

SAN DIEGO -- Aldevron announced today from the floor of the Festival of Biologics in San Diego, its expansion plans for its Freiburg, Germany facility.  The Freiburg location houses the GENOVAC antibody development platform and became the second site for Aldevron in 2004.

Read More